Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer

• Main Authors: Chow, L.Q.M (Author), Kwong, W.J (Author), Marrett, E. (Author)
• Format: Article
• Language: English
• Published: Future Medicine Ltd. 2022
• Subjects: African-Americans; aged; Aged; carcinoma; Carcinoma, Non-Small-Cell Lung; EGFR protein, human; EGFR TKI; epidemiology; epidermal growth factor receptor; ErbB Receptors; genetics; health services accessibility; human; Humans; Lung Neoplasms; lung tumor; medicare; Medicare; Medicare Part D; mutation; Mutation; non small cell lung cancer; non-small-cell lung cancer; pathology; protein kinase inhibitor; Protein Kinase Inhibitors; Retrospective Studies; retrospective study; rural population; SEER; time-To-Treatment; United States
• Online Access: View Fulltext in Publisher

 Aim: Assess factors associated with EGFR TKI initiation among patients with metastatic non-small-cell lung cancer (mNSCLC). Patients & methods: Medicare Part D patients diagnosed with non-squamous mNSCLC and starting an EGFR TKI within 1 year of diagnosis were selected from the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Associations between patient characteristics and time from diagnosis to treatment initiation (time-To-Treatment [TTT]) were analyzed. Results: Among the sample (n = 890), the patients who were younger, African-American or from rural communities had significantly longer TTT. Patients who did not receive surgery, who were Asian and those with brain metastases had significantly shorter TTT. Conclusion: Patient demographics and clinical characteristics may affect timeliness of EGFR TKI treatment for mNSCLC. Future research should examine potential barriers to treatment. © 2022 Daiichi Sankyo Inc.